Eli Lilly and [LLY] vs Gilead Sciences [GILD] Detailed Stock Comparison
Eli Lilly and
NYSE
Loading...
Gilead Sciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Eli Lilly and wins in 10 metrics, Gilead Sciences wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Eli Lilly and | Gilead Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 49.28 | 22.73 | Gilead Sciences |
| Price-to-Book Ratio | 37.07 | 7.23 | Gilead Sciences |
| Debt-to-Equity Ratio | 217.89 | 127.34 | Gilead Sciences |
| PEG Ratio | 0.54 | 1.05 | Eli Lilly and |
| EV/EBITDA | 28.85 | 11.66 | Gilead Sciences |
| Profit Margin (TTM) | 25.91% | 21.87% | Eli Lilly and |
| Operating Margin (TTM) | 45.81% | 39.16% | Eli Lilly and |
| EBITDA Margin (TTM) | 45.81% | 39.16% | Eli Lilly and |
| Return on Equity | 86.29% | 33.40% | Eli Lilly and |
| Return on Assets (TTM) | 16.55% | 12.62% | Eli Lilly and |
| Free Cash Flow (TTM) | $414.30M | $10.31B | Gilead Sciences |
| Dividend Yield | 0.52% | 3.25% | Gilead Sciences |
| 1-Year Return | -18.22% | 38.33% | Gilead Sciences |
| Price-to-Sales Ratio (TTM) | 12.72 | 4.92 | Gilead Sciences |
| Enterprise Value | $714.65B | $160.94B | Eli Lilly and |
| EV/Revenue Ratio | 13.42 | 5.58 | Gilead Sciences |
| Gross Profit Margin (TTM) | 84.27% | 78.80% | Eli Lilly and |
| Revenue per Share (TTM) | $59 | $23 | Eli Lilly and |
| Earnings per Share (Diluted) | $15.33 | $5.04 | Eli Lilly and |
| Beta (Stock Volatility) | 0.47 | 0.38 | Gilead Sciences |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Eli Lilly and vs Gilead Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Eli Lilly and | -0.12% | 3.88% | 18.13% | -6.98% | -8.09% | -2.91% |
| Gilead Sciences | -2.81% | -0.43% | -4.56% | 2.23% | 0.49% | 24.67% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Eli Lilly and | -18.22% | 144.55% | 389.97% | 753.64% | 2,010.62% | 1,268.46% |
| Gilead Sciences | 38.33% | 74.62% | 76.10% | 5.63% | 562.91% | 889.21% |
News Based Sentiment: Eli Lilly and vs Gilead Sciences
Eli Lilly and
News based Sentiment: POSITIVE
Eli Lilly delivered a strong Q2 2025, raised its guidance, and made significant progress in its pipeline across multiple therapeutic areas, including oncology and Alzheimer's. The launch of an AI-powered drug discovery platform further strengthens its long-term growth prospects, despite competition in the weight-loss market.
Gilead Sciences
News based Sentiment: MIXED
Gilead reported strong Q2 results and is making significant investments in manufacturing and HIV prevention, signaling growth potential. However, continued insider selling and mixed analyst sentiment introduce uncertainty, creating a complex investment picture. The combination of positive financial performance and strategic initiatives alongside these concerns warrants a 'mixed' assessment.
Performance & Financial Health Analysis: Eli Lilly and vs Gilead Sciences
| Metric | LLY | GILD |
|---|---|---|
| Market Information | ||
| Market Cap | $691.79B | $142.13B |
| Market Cap Category | Mega cap | Large cap |
| 10 Day Avg. Volume | 2,877,030 | 6,749,120 |
| 90 Day Avg. Volume | 5,555,130 | 6,467,877 |
| Last Close | $755.39 | $114.55 |
| 52 Week Range | $623.78 - $942.35 | $81.57 - $121.83 |
| % from 52W High | -19.84% | -5.98% |
| All-Time High | $972.53 (Aug 19, 2024) | $123.37 (Jun 22, 2015) |
| % from All-Time High | -22.33% | -7.15% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.38% | 0.02% |
| Quarterly Earnings Growth | 0.91% | 0.21% |
| Financial Health | ||
| Profit Margin (TTM) | 0.26% | 0.22% |
| Operating Margin (TTM) | 0.46% | 0.39% |
| Return on Equity (TTM) | 0.86% | 0.33% |
| Debt to Equity (MRQ) | 217.89 | 127.34 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $20.38 | $15.84 |
| Cash per Share (MRQ) | $3.95 | $4.88 |
| Operating Cash Flow (TTM) | $10.94B | $9.87B |
| Levered Free Cash Flow (TTM) | $-2,265,437,440 | $8.84B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.52% | 3.25% |
| Last 12-Month Dividend | $4.10 | $3.91 |
Valuation & Enterprise Metrics Analysis: Eli Lilly and vs Gilead Sciences
| Metric | LLY | GILD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 49.28 | 22.73 |
| Forward P/E | 33.34 | 15.42 |
| PEG Ratio | 0.54 | 1.05 |
| Price to Sales (TTM) | 12.72 | 4.92 |
| Price to Book (MRQ) | 37.07 | 7.23 |
| Market Capitalization | ||
| Market Capitalization | $691.79B | $142.13B |
| Enterprise Value | $714.65B | $160.94B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 13.42 | 5.58 |
| Enterprise to EBITDA | 28.85 | 11.66 |
| Risk & Other Metrics | ||
| Beta | 0.47 | 0.38 |
| Book Value per Share (MRQ) | $20.38 | $15.84 |
Financial Statements Comparison: Eli Lilly and vs Gilead Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | LLY | GILD |
|---|---|---|
| Revenue/Sales | $12.73B | $6.67B |
| Cost of Goods Sold | $2.22B | $1.54B |
| Gross Profit | $10.50B | $5.13B |
| Research & Development | $2.73B | $1.38B |
| Operating Income (EBIT) | $5.41B | $2.49B |
| EBITDA | $5.92B | $3.28B |
| Pre-Tax Income | $3.46B | $1.65B |
| Income Tax | $696.80M | $334.00M |
| Net Income (Profit) | $2.76B | $1.32B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | LLY | GILD |
|---|---|---|
| Cash & Equivalents | $3.09B | $7.93B |
| Total Current Assets | $41.26B | $16.90B |
| Total Current Liabilities | $30.07B | $12.34B |
| Long-Term Debt | $34.50B | $22.15B |
| Total Shareholders Equity | $15.85B | $19.08B |
| Retained Earnings | $15.10B | $10.93B |
| Property, Plant & Equipment | N/A | $7.96B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | LLY | GILD |
|---|---|---|
| Operating Cash Flow | $4.88B | $1.56B |
| Capital Expenditures | $-1.51B | $-104.00M |
| Free Cash Flow | $-1.60B | $1.65B |
| Debt Repayment | N/A | $-1.76B |
| Common Stock Repurchase | $-1.20B | $-730.00M |
Short Interest & Institutional Ownership Analysis
| Metric | LLY | GILD |
|---|---|---|
| Shares Short | 8.04M | 17.56M |
| Short Ratio | 1.22 | 2.79 |
| Short % of Float | 0.01% | 0.01% |
| Average Daily Volume (10 Day) | 2,877,030 | 6,749,120 |
| Average Daily Volume (90 Day) | 5,555,130 | 6,467,877 |
| Shares Outstanding | 897.54M | 1.25B |
| Float Shares | 895.44M | 1.24B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.84% | 0.91% |
Dividend Analysis & Yield Comparison: Eli Lilly and vs Gilead Sciences
| Metric | LLY | GILD |
|---|---|---|
| Last 12-Month Dividend | $4.10 | $3.91 |
| Last 12-Month Dividend Yield | 0.52% | 3.25% |
| 3-Year Avg Annual Dividend | $4.02 | $3.30 |
| 3-Year Avg Dividend Yield | 0.22% | 0.91% |
| 3-Year Total Dividends | $12.05 | $9.91 |
| Ex-Dividend Date | Feb 14, 2025 | Sep 15, 2025 |